Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults

Next Previous
Trial Profile

A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Mar 2025 According to a Blue Lake Biotechnology media release, company announced that it will be presenting safety and immunogenicity data on BLB201 at the 13th International RSV Symposium, occurring March 12-15 in Iguazu, Brazil.
  • 25 Oct 2023 According to a Blue lake biotechnology media release, data from this study were published in Science Advances.
  • 25 Oct 2023 Results were published in a Blue lake biotechnology Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top